Oral News and Research

RSS

Baby boomers more likely to develop HCV

Experts at Montefiore Medical Center urge the general public to be tested for the Hepatitis C virus, especially baby boomers, adults born between 1946-1964, who could be most at risk for this disease. Baby boomers are more likely to have been exposed to dangerous risk factors decades ago, such as sharing a drug needle, being tattooed or pierced with unsterilized tools or receiving a tainted blood transfusion.

2 Dec 2011

Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company.

2 Dec 2011

Obstacles people with type 2 diabetes face that prevent them from getting ultimate treatment

Eli Lilly and Company today announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals.

2 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Novel interventions promote CPAP use among people with OSA

People with obstructive sleep apnea are more likely to stick to prescribed treatment when a partner or parent is involved with their treatment, according to a team of sleep researchers.

2 Dec 2011

Registration for Kessler Foundation's 24th Annual PM&R Board Review Course now open

Registration for Kessler Foundation's 24th Annual Physical Medicine and Rehabilitation (PM&R) Board Review Course, the nation's largest review course in the field of PM&R, is now open! Register before January 16th for early bird discount.

2 Dec 2011

Mylan confirms generic Generess Fe patent challenge

Mylan Inc. today confirmed that it and Famy Care Ltd. have been sued by Warner Chilcott Company LLP, in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets, 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This product is the generic version of Generess Fe, a 28-day regimen indicated for use by women to prevent pregnancy.

2 Dec 2011

Conference to explore acute ischemic stroke treatment

Designed to serve a multidisciplinary audience of physicians, clinicians, and scientists interested in cerebrovascular disease, this 2.5-day conference will explore the state-of-the-art and future directions of research and clinical practice leading to enhanced medical care in the acute treatment of ischemic stroke.

1 Dec 2011

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

1 Dec 2011

Oral ingestion of apple polyphenols can prevent colitis in mice

Here's another reason why "an apple a day keeps the doctor away"-according to new research findings published in the Journal of Leukocyte Biology, oral ingestion of apple polyphenols can suppress T cell activation to prevent colitis in mice.

1 Dec 2011

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Nov 2011

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

30 Nov 2011

Tricky issues surround Supreme Court's health law review

Should the arguments heard by the high court regarding the health law be televised on C-SPAN? And should certain justices step away from the case? These are among the key questions that continue to buzz around the health law's day in court.

30 Nov 2011

MSF addresses Cameroon cholera epidemic

This post on Medecins Sans Frontiere's (MSF) website describes the humanitarian organization's activities in Cameroon to address a 14-month-long cholera epidemic.

30 Nov 2011

FDA approves Watson's ANDA for generic Yaz oral contraceptive

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz oral contraceptive product.

29 Nov 2011

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

29 Nov 2011

First Edition: November 29, 2011

Reporting for Kaiser Health News, and working in collaboration with The Washington Post, Sandra G. Boodman writes: "Propelled by the Post-9/11 GI Bill, which took effect in 2009, 2 million veterans, many of whom served in Iraq and Afghanistan, are eligible for generous benefits that can amount to a full scholarship.

29 Nov 2011

Testing of vaginal gel for HIV prevention halted after interim results showed no difference from placebo

Researchers involved with a multi-armed clinical trial designed to evaluate different antiretroviral (ARV) interventions for HIV prevention on Friday announced the arm testing a vaginal gel had been stopped because it was not working, the New York Times reports.

29 Nov 2011

Ferrer introduces citicoline oral solution medical food

Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.

29 Nov 2011

Daily inhaled steroids comparable to use of intermittent steroid treatment for wheezing

Pediatricians often treat young children who have frequent bouts of wheezing with a daily dose of an inhaled steroid to keep asthma symptoms at bay. But results of a recent study are likely to change that.

29 Nov 2011

Oral News and Research

Baby boomers more likely to develop HCV

Bristol-Myers Squibb, Tibotec partner for TMC435 Phase II combination study in HCV

Obstacles people with type 2 diabetes face that prevent them from getting ultimate treatment

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

Novel interventions promote CPAP use among people with OSA

Registration for Kessler Foundation's 24th Annual PM&R Board Review Course now open

Mylan confirms generic Generess Fe patent challenge

Conference to explore acute ischemic stroke treatment

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Oral ingestion of apple polyphenols can prevent colitis in mice

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Tricky issues surround Supreme Court's health law review

MSF addresses Cameroon cholera epidemic

FDA approves Watson's ANDA for generic Yaz oral contraceptive

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation

First Edition: November 29, 2011

Testing of vaginal gel for HIV prevention halted after interim results showed no difference from placebo

Ferrer introduces citicoline oral solution medical food

Daily inhaled steroids comparable to use of intermittent steroid treatment for wheezing

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News